OUR STORY

Organ Transport Systems, Inc. (“OTS”) was founded in Houston, Texas in mid-1999 by Hyman P. White. Earlier that year, he had been approached by shareholders of International Organ Transport Systems, Inc. who sought to turnaround their fledgling company whose purpose was to commercialize an organ preservation technology conceived at the University of Texas Health Science Center at San Antonio. Although the predecessor company eventually discontinued operations, Mr. White forged ahead with OTS inspired by the death of a friend with severe cardiomyopathy who could not get a heart for transplant. Mr. White’s focus on the humanitarian impact of OTS become a cornerstone of the Company’s corporate mission and culture which continues today.

EARLY YEARS

In early 2000, OTS was assigned its Original Patent for organ preservation as a part of a Settlement Agreement ratified by the Shareholders of the predecessor company. In late 2000, the first OTS prototype with the Original Patented design was taken to Australia where a series of transplant studies, using a special breed of swine whose hearts are similar to the human heart were completed. Under the director of an Australian transplant team led by Dr. Peter MacDonald, these successful transplants demonstrated a “proof of concept” that organs can be sustained for 12 hours. The series also revealed that the pneumatic piston-driven pump was not reliable.

Mr. Marlin Alford, an inventor associated with the Original Patent, and Robert M. Dowben, M.D., Ph.D., (“the Inventors”) came up with a completely unique 2nd generation. The Inventors filed a new patent which now has been issued (# US 6,677,150) and assigned to OTS, (the “Second Patent”). This patent provides broad coverage for hypothermic organ preservation using oxygenated perfusion by a nutrient solution and is not organ specific. The patent legal work was handled by McAndrews, Held and Malloy Ltd, a leading medical device patent firm. As a result the more effective design, OTS elected to pursue development of an improved device utilizing the Second Patent and abandoned the Original Patent.

A prominent engineer at Penn State University, George Panol, did the drawings for a further improved device. Mr. Panol was an important member of the team involved with the early heart-lung machines and development of an artificial heart. Tommy Davis, P.E, from Dallas, Texas. was hired as an independent contractor. He was able to improve the Alford/Dowben design by integrating a three-compartment design into a single-compartment design. The associated 3rd generation working prototype was finished in late 2001.

In 2001, through the significant efforts of Paul Rochester, an early OTS management team member and shareholder, OTS executed a Sponsored Research Agreement (SRA) with Texas Tech University Health Science Center in Lubbock, Texas. Mr. Rochester’s father had been a key financial supporter of the early organ preservation program at the University of Texas Health Science Center at San Antonio. Under the direction of Ari Halldorsson, M.D. and Sam Prien, Ph.D., transplant experiments were conducted from 2001-2006 and were supported financially by the State of Texas’ Advanced Technology Program and OTS. This research was successful in evaluating bio-chemical markers in transplants of swine hearts preserved from 4-24 hours, testing various device components, perfusion solution parameters, as well as in determining actual heart temperature levels experienced with static cold storage experiments. The research resulted in many presentations at regional, national, and international cardiac transplant peer group conferences.

In 2003, OTS relocated from Houston to Frisco, Texas to become the first program company at the North Texas Enterprise Center, a medical technology incubator with a mission to assist entrepreneurs to develop technology into successful commercial enterprises. OTS owes a debt of gratitude to NTEC for the valuable assistance and resources they provided which were important in the Company’s evolution. OTS became the first NTEC program company to graduate from the incubator in late 2006 after successful completion of certain corporate milestones.

In 2003-2004, OTS began work on the 4th generation prototype led by Marshall Wenrich under a contractual arrangement with The Realtime Group in Plano, Texas. This device was then used for continuing research at the Texas Tech University Health Science Center, Texas Heart Institute, as well as new research begun at The University of Texas Southwestern Medical Center in Dallas.

RECENT YEARS

In early 2005, Michael Holder was named OTS Chairman and CEO to accelerate and lead the Company in its fundraising and along its pathway to commercialization and shareholder value realization. Thereafter, Mr. Holder developed and the Company implemented a strategy to attract a world-class management team, board of directors and medical advisory board and to prioritize key corporate milestones that enabled three successful rounds of financings during 2005-2008. With the enhanced teams and additional capital, the Company made considerable progress in all facets of the business leading to its eventual sale to Healthcare of Today, Inc. in June 2010.

After Mr. Holder joined the OTS team, Dr. Tom Franklin transitioned from a part-time consulting role to an OTS Board Member and EVP of Research and Regulatory Affairs. Dr. Franklin has been instrumental in leading the development of the Medical Advisory Board, the Clinical Steering Committee team, establishing an FDA pathway, achieving research objectives and with building relations with many of the leading international cardiac transplant centers. Soon thereafter, Howell Warner was hired as VP Market and Customer Development and immediately became invaluable to the team as our “voice from the transplant and organ procurement community” and as a result of his unique ability to strongly contribute to multiple facets of the business. Specifically, he has added tremendous value in OTS research, product development and with various corporate technology initiatives. In early 2005, Susie Bodnar assumed the OTS Controller position and added significant value in accounting, audit, and with other financial activities of the Company. Hyman White was retained as a Board Member and EVP of Business Development and Governmental Relations. He has introduced many key relationships to the Company, strongly contributed to the company’s fundraising activities and has provided a valuable bridge with early shareholders and other key stakeholders.

Another key addition to OTS occurred in 2006 when past U.S. Dept. of Health and Human Services Secretary Tommy Thompson, a strong advocate for organ donation and transplantation, joined the OTS Board of Directors. Further additions to the OTS Board of Directors included Gene Pierce, Chairman Emeritus of the United Network for Organ Sharing; Dr. Marvin Slepian, Chairman of Syncardia and Director of Interventional Cardiology at the University of Arizona Sarver Heart Center; and Dr. Bridget Duffy, former Medical Director at St. Jude Medical and Executive Director at the Cleveland Clinic Heart-Brain Institute. In 2007, Dr. Bob Kormos, a recent past President of the International Society for Heart and Lung Transplantation from the University of Pittsburgh joined the OTS Medical Advisory Board thus providing enhanced credibility for the Company in the transplant community.

Perhaps no individual has played a more key role in the development of the LifeCradle® technology and solution than Michael Jessen, M.D., Professor and Chairman, Department of Cardiothoracic Surgery at UT Southwestern Medical Center at Dallas and Principal Investigator of the OTS research project at UT Southwestern. Dr. Jessen and his team consisting of Dr. David Rosenbaum, Dr. Matthias Peltz, and Michael Cobert have been funded by OTS and by the State of Texas Advanced Technology Program to further define applications of the OTS LifeCradle® technology in donor organ perfusion and preservation. They have worked tirelessly in the laboratory to evaluate optimal preservation conditions for hearts while studying oxidative metabolism, tissue lactate levels, myocardial cell damage, water retention, and many other heart preservation parameters. As a result, the foundation of the OTS technology has been well documented in many peer-reviewed publications and presentations made by Dr. Jessen and his team. They recently have conducted research with discarded human hearts that has provided valuable information supporting the ease of using the LifeCradle® in the “real world” procurement environment.

In late 2005, with the core team and investor capital in place, the company accelerated product development efforts with the Realtime Group. OTS utilized an outsourced product development strategy to minimize capital investment and to ensure “best of class” capabilities. Several key vendors were added for industrial design, cognitive ergonomics, assembly, and packaging. Additionally, OTS designed and implemented a Quality Assurance Initiative in 2006-2007. A second OTS patent was issued in 2007 with 35 claims as a continuation of the original OTS patent. Based largely upon product development activities, OTS has filed for other patents in recent years that are either pending or have been granted in the US, Europe, Australia, and South Africa.

From 2005 to date, OTS staff has visited with transplant teams and OPO representatives from over 30 cardiac transplant centers who have provided guidance and insight into the both the LifeCradle® as well as our research and FDA/CE Marking strategies. Further, several cardiac programs among the top 20 in the U.S. and Europe actively reviewed and evaluated product concepts, illustrations, and prototypes to arrive at the commercial LifeCradle® design.

Today, OTS is in the latter stages of finalizing development and initiating the manufacturing of the commercial LifeCradle® HR device for cardiac applications in preparation for a European clinical study at leading transplant centers as well as a clinical trial in the US. In addition to its work with the LifeCradle® HR heart device, OTS has proceeded with conceptual work on several other organ disciplines since 2006 including the LifeCradle® lung device and liver device. Research also has been undertaken with unique perfusion solutions that aid in the preservation of the donor heart and other organs.

In late 2009, OTS was introduced to Healthcare of Today, Inc. as a potential funding source. A shared corporate vision and commitment to quality healthcare led to the acquisition of OTS by Healthcare of Today, Inc. in June 2010.

In March 2011, Allezoe Medical Holdings, Inc. (OTCBB:ALZM) announced that it had acquired Organ Transport Systems, Inc. (OTS) from Healthcare of Today, Inc. in an all stock transaction. The acquisition of OTS is the first of several planned acquisitions by Allezoe Medical Holdings (“Allezoe”) in the medical device development, manufacturing and related services market. As a result of the acquisition, Michael Holder, President, CEO and Director of OTS, and Hyman White, Secretary, Treasurer and Director of OTS, have been appointed to the Board of Directors of ALZM. Mr. Holder will serve as the CEO of Allezoe and Mr. White as its Secretary and Treasurer.

In March 2011, OTS welcomed Gene Pierce, the “patriarch of organ sharing” and Chairman Emeritus of the United Network for Organ Sharing to its Board of Advisors.